131 related articles for article (PubMed ID: 2471962)
1. Development of monoclonal antibody imaging of metastatic prostatic carcinoma.
Meyers FJ; Denardo SJ; Macey D; White RD; Unger M
Prostate; 1989; 14(3):209-20. PubMed ID: 2471962
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors.
Schlom J; Colcher D; Szpak CA; Johnston WW; Sugarbaker P; Carrasquillo JA; Reynolds JC; Larson SM
Prog Clin Biol Res; 1989; 288():63-72. PubMed ID: 2717642
[No Abstract] [Full Text] [Related]
3. Monoclonal antibody that defines the prostate specific antigen.
Donn F; Bruns T; von Meyerinck L; Schulz M; Becker WM; Becker H; Klosterhalfen H
Prostate; 1989; 14(3):237-49. PubMed ID: 2471963
[TBL] [Abstract][Full Text] [Related]
4. Production of monoclonal antibody against human prostatic adenocarcinoma and its immunohistochemical properties.
Matsuki H; Ozono S; Yoshie T; Kubota K; Hirao Y; Konishi N; Hashimoto H; Ohshima M; Hiasa Y; Okajima E
Jpn J Exp Med; 1990 Oct; 60(5):263-72. PubMed ID: 1706786
[TBL] [Abstract][Full Text] [Related]
5. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with intra lymphatic administration of 111In-labelled monoclonal antibody PAY 276 for the detection of pelvic nodal metastases in prostatic carcinoma.
Abdel-Nabi HH; Ortman-Nabi JA; See W; Lee J; Ireton R; Boileau M; Unger MW; Halverson C
Eur J Nucl Med; 1990; 16(3):149-56. PubMed ID: 2364957
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the safety and accuracy of intraoperative gamma probe directed biopsy of bone scan detected rib abnormalities in prostatic adenocarcinoma.
Thurman SA; Robinson LA; Ahmad N; Pow-Sang JM; Lockhart JL; Seigne J
J Urol; 2003 Apr; 169(4):1341-4. PubMed ID: 12629356
[TBL] [Abstract][Full Text] [Related]
8. Targeting of cancer cells with monoclonal antibodies specific for C3b(i).
Sokoloff MH; Nardin A; Solga MD; Lindorfer MA; Sutherland WM; Bankovich AJ; Zhau HE; Chung LW; Taylor RP
Cancer Immunol Immunother; 2000 Dec; 49(10):551-62. PubMed ID: 11129326
[TBL] [Abstract][Full Text] [Related]
9. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer imaging with a new monoclonal antibody: a preliminary report.
Sanford E; Grzonka R; Heal A; Helal M; Persky L; Tyson I
Ann Surg Oncol; 1994 Sep; 1(5):400-4. PubMed ID: 7850541
[TBL] [Abstract][Full Text] [Related]
11. The role of monoclonal antibody in the management of prostate adenocarcinoma.
Texter JH; Neal CE
J Urol; 1998 Dec; 160(6 Pt 2):2393-5. PubMed ID: 9817390
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunodetection of prostatic cancer with 125I-labelled antibody against prostatic specific antigen.
Larson A; Arnberg H; Maripuu E; Nilsson S
Scand J Urol Nephrol Suppl; 1988; 110():149-53. PubMed ID: 2460917
[TBL] [Abstract][Full Text] [Related]
13. [Prostatic adenocarcinoma: pathological stage C. I: Diagnosis, technical aspects and significance].
Flam T; Zerbib M; Steg A; Debré B
J Urol (Paris); 1991; 97(1):5-9. PubMed ID: 1707935
[No Abstract] [Full Text] [Related]
14. Critical assessment of prostate cancer staging.
Graham SD
Cancer; 1992 Jul; 70(1 Suppl):269-74. PubMed ID: 1376195
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer.
Slovin SF; Scher HI; Divgi CR; Reuter V; Sgouros G; Moore M; Weingard K; Pettengall R; Imbriaco M; El-Shirbiny A; Finn R; Bronstein J; Brett C; Milenic D; Dnistrian A; Shapiro L; Schlom J; Larson SM
Clin Cancer Res; 1998 Mar; 4(3):643-51. PubMed ID: 9533532
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen.
Carroll AM; Zalutsky M; Schatten S; Bhan A; Perry LL; Sobotka C; Benacerraf B; Greene MI
Clin Immunol Immunopathol; 1984 Nov; 33(2):268-81. PubMed ID: 6488592
[TBL] [Abstract][Full Text] [Related]
17. [Carcinoma of the prostate: correlation between local staging and systemic progression].
Rosi P; Marzi M; Mearini E; Bracarda S; Valli PP; Petroni PA; Porena M
Arch Ital Urol Androl; 1996 Dec; 68(5 Suppl):91-5. PubMed ID: 9162385
[TBL] [Abstract][Full Text] [Related]
18. A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27.
Wright GL; Beckett ML; Lipford GB; Haley CL; Schellhammer PF
Int J Cancer; 1991 Mar; 47(5):717-25. PubMed ID: 1706326
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer.
Miller PD; Eardley I; Kirby RS
Br J Urol; 1992 Sep; 70(3):295-8. PubMed ID: 1384920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
